Caroline Gordon researcher, ORCID id # 0000-0002-1244-6443
Gordon, Caroline, 1956-
Gordon, Caroline.
Gordon, C.
Gordon, C. (Caroline)
Gordon, Caroline, 1956-.... (médecin)
VIAF ID: 161132057 (Personal)
Permalink: http://viaf.org/viaf/161132057
Preferred Forms
- 100 0 _ ‡a Caroline Gordon ‡c researcher, ORCID id # 0000-0002-1244-6443
- 100 1 _ ‡a Gordon, C.
-
- 100 1 _ ‡a Gordon, Caroline
-
- 100 1 _ ‡a Gordon, Caroline ‡d 1956-
-
-
- 100 1 _ ‡a Gordon, Caroline, ‡d 1956-
- 100 1 _ ‡a Gordon, Caroline, ‡d 1956-.... ‡c (médecin)
-
4xx's: Alternate Name Forms (3)
5xx's: Related Names (1)
Works
Title | Sources |
---|---|
Connective tissue diseases : an atlas of investigation and management | |
Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial | |
Numerical scoring for the Classic BILAG index | |
Oral abstracts 1: Spondyloarthropathies * O1. Detecting axial spondyloarthritis amongst primary care back pain referrals | |
Population-based lupus registries: Advancing our epidemiologic understanding | |
Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program | |
Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL. | |
Postgraduate degrees for rheumatology trainees: an options appraisal of MD, PhD and MSc degrees. On behalf of the BSR Research and Training Committee | |
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales | |
Pregnancy and reproduction in autoimmune rheumatic diseases | |
The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients | |
The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth | |
Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study | |
Prevalence of Mixed Connective Tissue Disease in a Population-Based Registry of American Indian/Alaska Native People in 2007. | |
Primary anti-phospholipid antibody syndrome (APS): current concepts | |
Pulmonary arterial hypertension in SLE: what do we know? | |
Quality of life and economic evaluation in SLE clinical trials. | |
Racial Disparities in Mortality Associated with Systemic Lupus Erythematosus - Fulton and DeKalb Counties, Georgia, 2002-2016. | |
Racial Disparities in the Incidence of Primary Chronic Cutaneous Lupus Erythematosus in the Southeastern US: The Georgia Lupus Registry | |
Refractory multisystem sarcoidosis responding to infliximab therapy | |
SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus | |
Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. | |
SLE patients with renal damage incur higher health care costs. | |
The SLICC damage index: past, present and future | |
Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. | |
Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus | |
Stratifying management of rheumatic disease for pregnancy and breastfeeding | |
The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey | |
Sulfasalazine induced seizures and dysphasia. | |
Synovial fluid leukocyte apoptosis is inhibited in patients with very early rheumatoid arthritis | |
Systemic lupus and malignancies | |
Systemic lupus erythematosus : a companion to Rheumatology | |
Systemic lupus erythematosus / [ed. by] George C. Tsokos, Caroline Gordon, Josef S. Smolen. - Philadelphia, cop. 2007. | |
Systemic lupus erythematosus into the next millennium: looking into the crystal ball | |
The systemic lupus erythematosus tri-nation study: longitudinal changes in physical and mental well-being. | |
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology | |
Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus | |
Tumor necrosis factor alpha activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint | |
Układowy toczeń rumieniowaty | |
Ultrasound guidance allows accurate needle placement and aspiration from small joints in patients with early inflammatory arthritis | |
Underestimating the value of women: assessing the indirect costs of women with systemic lupus erythematosus. Tri-Nation Study Group. | |
Unilateral varicella zoster virus ophthalmicus and contralateral acute retinal necrosis | |
Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs | |
Urinary IL-6: a marker for mesangial proliferative glomerulonephritis? | |
Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid antibody syndrome. | |
The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients | |
Usefulness of the British Isles Lupus Assessment Group index in pediatric clinical trials: comment on the article by Ruperto et al | |
Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus |